BridgeMD
New treatment option for Heart Failure
Official title Identifying Markers of Exercise Training in Heart Failure
ClinicalTrials.gov ID: NCT05696652
What this study is testing
- What it's testing
- The heart failure syndrome that occurs when the heart is too sick to properly do its job. One of the main symptoms is difficulty with exercise.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 89
You may be able to join if
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male or female, aged 18-89
- Patients must carry a diagnosis of heart failure with ejection fraction \< 40%
- Be willing to participate in cardiac rehabilitation, and not already done so in the last year
You likely can't join if
- Inability to complete CPET or participate in CR (verbal/chart)
- Syncope during CPET within the last 6 mos, sustained VT on CPET, hemodynamically significant arrhythmia during CPET (verbal/chart)
- BMI \>= 38 (verbal/chart)
- History of a bleeding disorder or clotting abnormality (verbal/chart)
- Clinical diagnosis of severe Chronic Obstructive Pulmonary Disease (COPD) (verbal/chart)
- History of malignancy not considered in remission (verbal/chart)
See the full eligibility criteria
Who can join
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male or female, aged 18-89
- Patients must carry a diagnosis of heart failure with ejection fraction \< 40%
- Be willing to participate in cardiac rehabilitation, and not already done so in the last year
- Agreement to adhere to Lifestyle Considerations (see section 5.3) throughout study duration
- Must be able to exercise on a treadmill
What rules you out
- Inability to complete CPET or participate in CR (verbal/chart)
- Syncope during CPET within the last 6 mos, sustained VT on CPET, hemodynamically significant arrhythmia during CPET (verbal/chart)
- BMI \>= 38 (verbal/chart)
- History of a bleeding disorder or clotting abnormality (verbal/chart)
- Clinical diagnosis of severe Chronic Obstructive Pulmonary Disease (COPD) (verbal/chart)
- History of malignancy not considered in remission (verbal/chart)
- Cirrhosis (verbal/chart)
- Thyroid disease (verbal/chart)
- Thyroid Stimulating Hormone (TSH) value outside of the normal range for the laboratory within the last 1 year
- Individuals with hypothyroidism may be referred to their primary care provider (PCP) for evaluation and retested; any medication change must be stable for ≥3 months prior to retesting
- Individuals with hyperthyroidism are excluded, including those with normal TSH on pharmacologic treatment
- Cancer (verbal/chart)
- History of cancer treatment (other than non-melanoma skin cancer) and not "cancer-free" for at least 2 years
- Anti-hormonal therapy (e.g., for breast or prostate cancer) within the last 6 months
- Chronic active or latent infection (verbal/chart)
- Active or latent infections requiring chronic antibiotic or anti-viral treatment
- Chronic active infection whether on chronic antimicrobials or not
- Human Immunodeficiency Virus
- Active hepatitis B or C undergoing antiviral therapy
- Individuals successfully treated for hepatitis C and virologically negative for at least 6 months are not excluded
- Tobacco (verbal/chart)
- Current smokers: any tobacco or e-cigarette/e-nicotine products
- Former smokers: Stopped smoking \<6 months at time of screening
- Not be pregnant or lactating in the last 12 months, or planning to become pregnant for the next 4 months. Not be post-partum during the last 12 months. (verbal/chart)
- Metabolic bone disease (self-report): History of non-traumatic fracture from a standing height or less. Current pharmacologic treatment for low bone mass or osteoporosis, other than calcium, vitamin D, or estrogen...
- Diabetes (self-report and screening), which includes: i) treatment with any insulin or ii) A1c \>=8.0 (screening). (verbal/chart)
- Chronic renal insufficiency (screening): estimated glomerular filtration rate \<30 mL/min/1.73 m2 from serum creatinine (mg/dL) by the Chronic Kidney Disease Epidemiology Collaboration equation. (verbal/chart)
- Individuals receiving any active treatment for autoimmune disorders (including monoclonal antibodies) within the last 6 months. (verbal/chart)
- Alcohol consumption: i) more than 7 drinks per week for women and more than 14 drinks per week for men; ii) history of binge drinking. (verbal/chart)
- Any individual engaging in night shift work in the last 6 months.
- Hospitalization for any psychiatric condition within one year (verbal/chart)
- Any musculoskeletal or ligamentous injury, amputation or congenital neurological defect that, in the opinion of the team clinician, would negatively impact or mitigate participation in and completion of the protocol...
- Mental incapacity and/or cognitive impairment on the part of the participant that would inhibit adequate understanding of or cooperation with the study protocol
- Other (clinician judgment)
- Genetic metabolic disorders that could affect metabolomic results (e.g., phenylketonuria)
- Any other cardiovascular, pulmonary, orthopedic, neurologic, psychiatric, metabolic, or other conditions that, in the opinion of the local clinician, would preclude participation and successful completion of the protocol
- Any other illnesses that, in the opinion of the local clinician, would negatively impact or mitigate participation in and completion of the protocol
- Medication exclusions (chart review)
- Androgenic anabolic steroids, antiestrogens, antiandrogens
- Growth hormone, insulin like growth factor, growth hormone releasing hormone
- Insulin of any type used regularly
- Any drugs used specifically to induce muscle growth/hypertrophy or augment exercise induced muscle hypertrophy
- Psychiatric
- Chronic use of medium- or long-acting sedatives and hypnotics, including all benzodiazepines; short-acting non-benzodiazepine sedative-hypnotics are allowed
- Two or more drugs for depression
- Mood stabilizers
- Antiepileptic drugs
- Stimulants, Attention-Deficit/Hyperactivity Disorder (ADHD) drugs
- Anti-psychotic drugs
- Narcotics and narcotic receptor agonists
- Chronic systemic antimicrobials (antibiotic, antiviral, antifungal, antiparasite, etc) for any reason
- High-potency topical steroids if ≥10% of surface area using rule of 9s
- Continuous/chronic use of antibiotics or other anti-infectives for treatment or prevention
- Monoclonal antibodies
- Anti-rejection medications/immune suppressants
- Any other medications that, in the opinion of local clinicians, would negatively impact or mitigate full participation and completion.
The study team makes the final eligibility decision.
Where it's taking place
- Stanford, California, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 89 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Stanford, California, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.